GlassScriptPhysician profile
Chandler Dean Patton
NPI 1285604868
$4,249.24
in general payments reported to CMS, 2019-2025
26 companies · $358 in 2025
The $358 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $123 · 2021: $758 · 2022: $1,054 · 2023: $685 · 2024: $532 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,575.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $731.49 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $617.50 | 2019-2025 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $488.15 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $341.48 | 2019-2024 | Fasenra, Breztri, Tezspire |
| Janssen Pharmaceuticals, INC | $312.08 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.81 | 2019-2024 | Ofev |
| Genzyme Corporation | $208.16 | 2020-2025 | |
| Medtronic, INC. | $177.97 | 2022 | |
| Mallinckrodt Hospital Products INC. | $150.00 | 2024 | Terlivaz |
| Mylan Specialty L.P. | $146.51 | 2019-2024 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $142.75 | 2025 | Lumryz |
| Csl Behring | $133.60 | 2019-2021 | |
| Intuitive Surgical, INC. | $109.73 | 2023 | Da Vinci Surgical System |
| Harmony Biosciences LLC | $94.02 | 2021-2024 | Wakix |
| Philips North America LLC | $62.93 | 2019-2025 | Vest Therapy Und |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $46.94 | 2023-2024 | Tyvaso |
| Portola Pharmaceuticals, LLC | $44.78 | 2019 | |
| Covidien LP | $44.58 | 2019 | |
| Vapotherm INC | $34.64 | 2019 | |
| Merck Sharp & Dohme LLC | $31.01 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $30.39 | 2019-2024 | Dupixent |
| Viatris Specialty LLC | $20.24 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $18.87 | 2024 | |
| Pfizer INC. | $16.70 | 2022 | |
| Gilead Sciences, INC. | $11.66 | 2019 | |
| Allergan, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandler Patton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.